Monopar Therapeutics Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Monopar Therapeutics Inc. (MNPR) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$2.48 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2022-05-12
- Monopar Therapeutics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2022-03-31 was -$2.48M, a 127.65% decline year-over-year.
- Monopar Therapeutics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-09-30 was -$1.95M, a 135.89% decline year-over-year.
- Monopar Therapeutics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-06-30 was -$1.43M.
- Monopar Therapeutics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-03-31 was $8.99M.
- Monopar Therapeutics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2020 was $3.52M, a 44.26% decline from fiscal 2019.
- Monopar Therapeutics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2019 was $6.32M.
- Monopar Therapeutics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$2.89M, a 141.82% decline from fiscal 2017.
- Monopar Therapeutics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $6.91M, a 10079.94% increase from fiscal 2016.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$2.48M 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | -$1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$3.38M derived: sum of 2 quarters · filed 2021-11-12 | $5.60M 10-Q · filed 2021-11-12 | $4.36M derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-06-30 | -$1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $7.56M 10-Q · filed 2021-08-12 | $6.31M derived: sum of 3 quarters · filed 2022-05-12 | $11.75M derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-03-31 | $8.99M 10-Q · filed 2022-05-12 | $7.74M derived: sum of 2 quarters · filed 2022-05-12 | $13.18M derived: sum of 3 quarters · filed 2022-05-12 | $13.13M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $4.19M derived: sum of 2 quarters · filed 2021-11-12 | $4.14M derived: sum of 3 quarters · filed 2021-11-12 | $3.52M 10-K · filed 2021-03-25 |
| 2020-09-30 | $5.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $5.39M derived: sum of 2 quarters · filed 2021-11-12 | $4.77M 10-Q · filed 2021-11-12 | $13.49M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$46.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$667.74K 10-Q · filed 2021-08-12 | $8.05M derived: sum of 3 quarters · filed 2021-08-12 | $7.42M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$621.57K 10-Q · filed 2021-05-13 | $8.10M derived: sum of 2 quarters · filed 2021-05-13 | $7.46M derived: sum of 3 quarters · filed 2021-05-13 | $6.71M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $8.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $8.08M derived: sum of 2 quarters · filed 2021-03-25 | $7.33M derived: sum of 3 quarters · filed 2021-03-25 | $6.32M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$635.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$1.39M derived: sum of 2 quarters · filed 2020-11-12 | -$2.40M 10-Q · filed 2020-11-12 | -$3.12M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | -$751.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$1.76M 10-Q · filed 2020-08-06 | -$2.49M derived: sum of 3 quarters · filed 2020-08-06 | -$3.09M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | -$1.01M 10-Q · filed 2020-05-07 | -$1.74M derived: sum of 2 quarters · filed 2020-05-07 | -$2.34M derived: sum of 3 quarters · filed 2020-05-07 | -$3.09M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$725.49K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | -$1.33M derived: sum of 2 quarters · filed 2020-03-27 | -$2.08M derived: sum of 3 quarters · filed 2020-03-27 | -$2.89M 10-K · filed 2020-03-27 |
| 2018-09-30 | -$600.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$1.35M derived: sum of 2 quarters · filed 2019-11-12 | -$2.16M 10-Q · filed 2019-11-12 | -$2.97M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$754.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$1.56M 10-Q · filed 2019-08-08 | -$2.37M derived: sum of 3 quarters · filed 2019-08-08 | $3.94M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | -$808.85K 10-Q · filed 2019-05-10 | -$1.61M derived: sum of 2 quarters · filed 2019-05-10 | $4.69M derived: sum of 3 quarters · filed 2019-05-10 | $5.42M derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-12-31 | -$806.02K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $5.50M derived: sum of 2 quarters · filed 2019-02-26 | $6.23M derived: sum of 3 quarters · filed 2019-02-26 | $6.91M 10-K · filed 2019-02-26 |
| 2017-09-30 | $6.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $7.04M derived: sum of 2 quarters · filed 2018-11-09 | $7.71M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $729.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $1.41M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $678.52K 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $67.87K 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |